Cargando…

DNA direct reversal repair and alkylating agent drug resistance

DNA direct reversal repair (DRR) is unique in that no DNA synthesis is required to correct the error and therefore repair via such mechanisms are error-free. In humans, DRR is carried out by two different pathways: the O6-methylguanine-DNA methyltransferase (MGMT) and the alkylated DNA repair protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutierrez, Roberto, O’Connor, Timothy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019270/
https://www.ncbi.nlm.nih.gov/pubmed/35582025
http://dx.doi.org/10.20517/cdr.2020.113
_version_ 1784689222900252672
author Gutierrez, Roberto
O’Connor, Timothy R.
author_facet Gutierrez, Roberto
O’Connor, Timothy R.
author_sort Gutierrez, Roberto
collection PubMed
description DNA direct reversal repair (DRR) is unique in that no DNA synthesis is required to correct the error and therefore repair via such mechanisms are error-free. In humans, DRR is carried out by two different pathways: the O6-methylguanine-DNA methyltransferase (MGMT) and the alkylated DNA repair protein B (AlkB) homologs. The use of alkylating agents is the standard of care for many cancers. However, the use of those drugs is usually halted when resistance develops. This review will examine repair of alkylating agent damage mediated by DRR, resistance mechanisms and potential ways to overcome such resistance.
format Online
Article
Text
id pubmed-9019270
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-90192702022-05-16 DNA direct reversal repair and alkylating agent drug resistance Gutierrez, Roberto O’Connor, Timothy R. Cancer Drug Resist Review DNA direct reversal repair (DRR) is unique in that no DNA synthesis is required to correct the error and therefore repair via such mechanisms are error-free. In humans, DRR is carried out by two different pathways: the O6-methylguanine-DNA methyltransferase (MGMT) and the alkylated DNA repair protein B (AlkB) homologs. The use of alkylating agents is the standard of care for many cancers. However, the use of those drugs is usually halted when resistance develops. This review will examine repair of alkylating agent damage mediated by DRR, resistance mechanisms and potential ways to overcome such resistance. OAE Publishing Inc. 2021-06-19 /pmc/articles/PMC9019270/ /pubmed/35582025 http://dx.doi.org/10.20517/cdr.2020.113 Text en © The Author(s) 2021. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Gutierrez, Roberto
O’Connor, Timothy R.
DNA direct reversal repair and alkylating agent drug resistance
title DNA direct reversal repair and alkylating agent drug resistance
title_full DNA direct reversal repair and alkylating agent drug resistance
title_fullStr DNA direct reversal repair and alkylating agent drug resistance
title_full_unstemmed DNA direct reversal repair and alkylating agent drug resistance
title_short DNA direct reversal repair and alkylating agent drug resistance
title_sort dna direct reversal repair and alkylating agent drug resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019270/
https://www.ncbi.nlm.nih.gov/pubmed/35582025
http://dx.doi.org/10.20517/cdr.2020.113
work_keys_str_mv AT gutierrezroberto dnadirectreversalrepairandalkylatingagentdrugresistance
AT oconnortimothyr dnadirectreversalrepairandalkylatingagentdrugresistance